Physics and AI Driven Precision Engineering of Novel Drugs
Health + Time : Priceless
We Engineer New Treatments Atom by Atom
To help you live healthier, longer
Your browser does not support the video tag.
For a range of major human diseases, we’re developing treatments that cannot be found through any other method
For a range of major human diseases, we’re developing treatments that cannot be found through any other method
Your browser does not support the video tag.
First-in-Class Drug Candidates
to Change the Standard of Care for Every Disease We Address
PREVENTING HEART ATTACKS & STROKES WITH LOWER BLEEDING RISK
to help
185.7M
patients
2 Candidates
VE-1902, VE-2851
Stage: Clinical
PREVENTING & TREATING DIABETIC VISION LOSS WITHOUT EYE INJECTIONS
to help
179M
patients
2 Candidates
VE-4840, VE-3539
Stage: IND-Prep
PROVIDING CHEMO AGENTS FOR MULTIDRUG-RESISTANT CANCERS
to help
10M
patients
2 Candidates
VE-4054, VE-4932
Stage: Preclinical
PREVENTING AGGRESSIVE SOLID-TUMOR CANCER METASTASIS
to help
9M
patients
2 Candidates
VE-2843, VE-1787
Stage: Optimization
RESTORING IMMUNE RESPONE TO CD73 POSITIVE CANCERS
to help
6.5M
patients
2 Candidates
VE-3771, VE-5953
Stage: Preclinical
+
Many More…
Previous
Next
More about our pipeline
Recent News
First-in-Class Drug Candidates
to Change the Standard of Care for Every Disease We Address
PREVENTING HEART ATTACKS & STROKES WITH LOWER BLEEDING RISK
to help
185.7M
patients
2 Candidates
VE-1902, VE-2851
Stage: Clinical
PREVENTING & TREATING DIABETIC VISION LOSS WITHOUT EYE INJECTIONS
to help
179M
patients
2 Candidates
VE-4840, VE-3539
Stage: IND-Prep
PROVIDING CHEMO AGENTS FOR MULTIDRUG-RESISTANT CANCERS
to help
10M
patients
2 Candidates
VE-4054, VE-4932
Stage: Preclinical
PREVENTING AGGRESSIVE SOLID-TUMOR CANCER METASTASIS
to help
9M
patients
2 Candidates
VE-2843, VE-1787
Stage: Optimization
RESTORING IMMUNE RESPONE TO CD73 POSITIVE CANCERS
to help
6.5M
patients
2 Candidates
VE-3771, VE-5953
Stage: Preclinical
+
Many More…
Previous
Next
More about our pipeline
Recent News
Our stories
33 Zeroes: Verseon Advances AI Accuracy for Novel Small Molecule Designs
How new tech unlocks seemingly infinite chemical space
September 12, 2024
Drug Discovery AI Not Living Up to the Hype
Small-molecule drug discovery is hard. AI was supposed to make it easier. But it hasn't. What happened?
September 10, 2024
The Current State of Predicting Mortality and Disease
In a comprehensive systematic review of age-measurement literature, Verseon team members assess applicability, limitations, and clinical utility of epigenetic and phenotypic clocks
August 30, 2024
Verseon and NeuTherX Announce Partnership to Enhance Drug Development
Innovative technologies to improve drug-candidate selection and clinical-trial design
July 30, 2024
CEO Adityo Prakash Describes How Verseon Overcame AI's Data Limitations Using Quantum Physics Modeling
"What we have found at Verseon is that marrying physics with AI… allows you to efficiently explore the uncharted chemical ocean of possibilities to find the drugs of the future."
June 24, 2024
CEO Adityo Prakash Discusses How Verseon Overcame the Pitfalls of AI in Drug Discovery with A Geek Leader's John Rouda
"In small-molecule drug discovery AI clearly has a very big data problem. But you can get around this data problem if you combine AI with… breakthroughs in quantum physics."
May 24, 2024
Healthcare IT Today Discusses How Verseon Uses AI to Gain Additional Insights from Clinical-Trial Data
Verseon's analysis of patient data collected during clinical trials adds significant additional insight into progression of disease conditions and effects of therapeutic intervention.
MAY 22, 2024
Verseon's Drug Candidates Promise Hereditary Angioedema Treatment with Fewer Risks and Lower Cost
Examining previously inaccessible drug-like compounds with Deep Quantum Modeling opens the door to breakthrough medicines that offer better outcomes to patients
APRIL 23, 2024
33 Zeroes: Verseon Advances AI Accuracy for Novel Small Molecule Designs
How new tech unlocks seemingly infinite chemical space
September 12, 2024
Drug Discovery AI Not Living Up to the Hype
Small-molecule drug discovery is hard. AI was supposed to make it easier. But it hasn't. What happened?
September 10, 2024
The Current State of Predicting Mortality and Disease
In a comprehensive systematic review of age-measurement literature, Verseon team members assess applicability, limitations, and clinical utility of epigenetic and phenotypic clocks
August 30, 2024
Verseon and NeuTherX Announce Partnership to Enhance Drug Development
Innovative technologies to improve drug-candidate selection and clinical-trial design
July 30, 2024
CEO Adityo Prakash Describes How Verseon Overcame AI's Data Limitations Using Quantum Physics Modeling
"What we have found at Verseon is that marrying physics with AI… allows you to efficiently explore the uncharted chemical ocean of possibilities to find the drugs of the future."
June 24, 2024
CEO Adityo Prakash Discusses How Verseon Overcame the Pitfalls of AI in Drug Discovery with A Geek Leader's John Rouda
"In small-molecule drug discovery AI clearly has a very big data problem. But you can get around this data problem if you combine AI with… breakthroughs in quantum physics."
May 24, 2024
Healthcare IT Today Discusses How Verseon Uses AI to Gain Additional Insights from Clinical-Trial Data
Verseon's analysis of patient data collected during clinical trials adds significant additional insight into progression of disease conditions and effects of therapeutic intervention.
MAY 22, 2024
Verseon's Drug Candidates Promise Hereditary Angioedema Treatment with Fewer Risks and Lower Cost
Examining previously inaccessible drug-like compounds with Deep Quantum Modeling opens the door to breakthrough medicines that offer better outcomes to patients
APRIL 23, 2024
More News
Our stories
33 Zeroes: Verseon Advances AI Accuracy for Novel Small Molecule Designs
How new tech unlocks seemingly infinite chemical space
September 12, 2024
Drug Discovery AI Not Living Up to the Hype
Small-molecule drug discovery is hard. AI was supposed to make it easier. But it hasn't. What happened?
September 10, 2024
The Current State of Predicting Mortality and Disease
In a comprehensive systematic review of age-measurement literature, Verseon team members assess applicability, limitations, and clinical utility of epigenetic and phenotypic clocks
August 30, 2024
Verseon and NeuTherX Announce Partnership to Enhance Drug Development
Innovative technologies to improve drug-candidate selection and clinical-trial design
July 30, 2024
More News
Changing everything the world can expect from 21st Century Medicine
Continue to
Company
Your browser does not support the video tag.